1 Min Read
March 17 (Reuters) - Helix Biopharma Corp -
* Announces fiscal second quarter 2017 results and closing of private placement
* Q2 loss per share C$0.03
* Helix Biopharma Corp - "Will require additional financing in near term and in future"
* Cash balance of C$1.4 million, as at Jan 31, 2017, is insufficient to meet anticipated cash needs for working capital,capital expenditures
* Decided to substitute vinorelbine/cisplatin combination study going forward with study combining l-DOS47 with pemetrexed/carboplatin Source text for Eikon: Further company coverage: